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(QIV), comparing to TIV, in age-stratified populations of Hong Kong from 2001-2010 
years. Methods: TIV-unmatched influenza B infection rates with QIV versus TIV 
were estimated by an epidemiology model. Model parameters included percentages 
of influenza B lineages in circulation, influenza B-associated hospital admission, 
age-specific population, vaccine coverage and effectiveness. Events (outpatient 
care, hospitalizations and death) caused by infection of the influenza B lineage 
not included in TIV coverage in each year were calculated. Cost savings and QALYs 
gained from reduced events with QIV were estimated. Incremental cost per QALY 
gained (ICER) by QIV versus TIV were estimated from Hong Kong’s societal perspec-
tive. Results: All-age mean reduction in influenza B infection rate (per 100,000) 
was 25.9 (95%CI 6.7-45.1). Highest age-specific rate reduction was 451.4 (95%CI 87.7-
815.1) in ≥ 80 years, followed by 104.8 (95%CI 27.2-182.4) in 65-79 years and 13.2 
(95%CI 7.0-19.4) in 6 months-4 years. Highest cost savings and QALY gain occurred 
in years with high percentage (81.8%-96.4%) of circulated influenza B lineage not 
covered by TIV. QIV was more cost-effective than TIV in 6 years when it cost USD1 
more than TIV. When QIV was USD2, USD5 and USD10 more costly, it became cost-
effective in 3, 3 and zero years, respectively. ConClusions: QIV was cost-effective 
in very young and older populations. Cost-effectiveness of QIV was subjected to unit 
cost of QIV versus TIV and percentage of circulating influenza B lineages.
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objeCtives: Hong Kong is a developed city with intermediate tuberculosis (TB) 
burden of 90 per 100,000 population and low HIV prevalence. The diagnosis of TB 
in hospitalized patients was difficult due to atypical manifestation and low sen-
sitivity of sputum acid-fast bacilli (AFB) smear microscopy examination. Failure to 
receive early anti-TB treatment during initial assessment was identified to be an 
independent predictor associated with increased risk of mortality. We examined the 
cost-effectiveness of rapid diagnosis with Xpert MTB/RIF in patients hospitalized for 
suspected active pulmonary tuberculosis (PTB) from the perspective of Hong Kong 
public health care providers. Methods: A decision tree was designed to simulate 
outcomes of three diagnostic assessment strategies in adult patients hospitalized 
for suspected active PTB: conventional approach, sputum smear plus Xpert for AFB 
smear-negative, and a single sputum Xpert test. Model inputs were derived from 
literature. Outcome measures included direct medical cost, one-year mortality rate, 
quality-adjusted life-years (QALYs) and incremental cost per QALY (ICER). Results: 
In base-case analysis, one-year mortality rate of the Xpert group was 9.0% with 8.289 
QALYs gained. Comparing to smear plus Xpert, the Xpert group was more effective by 
an ICER of USD99. Conventional approach was the least preferred option with highest 
cost, lowest QALYs gained and highest mortality rate. Sensitivity analysis showed that 
Xpert would be the most cost-effective option if the sensitivity of sputum AFB smear 
microscopy was 74% or less. In 10,000 Monte Carlo simulations, the probabilities of 
Xpert, smear plus Xpert and conventional approach to be cost-effective were 94.5%, 
5.5% and 0%, respectively. ConClusions: Xpert sputum test appears to be a highly 
cost-effective diagnostic strategy for patients with suspected active PTB in intermedi-
ate burden area like Hong Kong.
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objeCtives: To estimate the cost effectiveness ratio of a inactivated quadrivalent 
influenza vaccine compared to the trivalent ones in France. Methods: During 
some epidemic influenza seasons a mismatch between the circulating B strains 
and the one included in the trivalent vaccine is observed. The difference of vaccine 
protection by the quadrivalent vaccine due to the inclusion of both circulating B 
strains should avoid the occurrence of a number of consultations and complications 
resulting in hospitalizations and deaths. A decision tree model was built to compare 
the efficacy and costs of the two vaccines for an average epidemic influenza season 
in the French setting. The number of hospitalization and deaths associated with 
influenza were estimated from an analysis of available French data. Estimates of 
these medical events were calculated using French standard costs in 2012 and obser-
vational data. Deterministic and probabilistic sensitivity analyses (PSA) were con-
ducted. Results: The base case analysis considered the global French vaccinated 
population during an average epidemic season between seasons 03/04 and 11/12 
with a B circulating virus rate of 23% and a mismatch rate of 58%. The perspective is 
collective. The number of avoided consultations for influenza was estimated at 6,214 
and the number of avoided hospitalizations and deaths at 614 and 372 respectively. 
The number of life years gained (LYG) was estimated at 5,382. The cost per LYG was 
estimated at 3,138€ /LYG. Sensitivity analyses showed clearly the importance of the 
B circulating virus rate combined with the mismatch rate highly variable according 
to influenza seasons. PSA showed that 100% of estimates in the acceptability curve 
were under 20,000€ per LYG in the base case analysis. ConClusions: The cost 
effectiveness ratio of an inactivated quadrivalent influenza vaccine compared to 
trivalent ones in the French setting can be considered acceptable.
PIN85
cost-effectIveNess of dolutegrAvIr, A New geNerAtIoN INtegrAse 
INhIbItor, IN hIv-1 treAtMeNt eXPerIeNced PAtIeNts IN frANce
Despiégel N.1, Marcellin A.G.2, Aubin C.3, Espinas C.1, Laurisse A.4, Pialoux G.5
1Optum, Nanterre, France, 2AP-HP, Hôpital Pitié-Salpêtrière, Paris, France, 3Glaxo Smith Kline, 
Marly-le-Roi, France, 4ViiV Healthcare France, Marly-le-Roi, France, 5APHP, Hôpital Tenon, Paris, 
France
per patient QALYs was 0.849 and 0.841 respectively. Viremia remained undetectable 
and CD4 stable in all patients. Additionally, other parameters such as Cholesterol, 
HDL and Triglycerides levels improved when switching from STR-containing EFV to 
Rilpivirine-based STR. VAS analysis of health status perception also increased over-
all from 82.78 to 83.79 (scale: 0-100) due to the improvement in the STR-containing 
RPV arm. STR with RPV dominated (i.e. was more effective and less costly) EFV STR 
regimen, as measured by outcomes. ConClusions: Switching from STR containing 
Efavirenz to STR containing Rilpivirine is a safe, well tolerated strategy that improves 
the overall health status of HIV–treated patients. The switch does not expose patients 
to a risk of virologic failure due to possible PK interactions of the drugs. RPV compared 
to EFV resulted cost-effective showing lower cost and higher outcome measure values.
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objeCtives: HIV is a life-threatening disease in terms of a major global public health 
problem. This analysis evaluates the cost-effectiveness comparison of HIV-1 treatment 
alternatives including lamivudine+zidovudine+efavirenz (3TC/AZT+EFV), tenofovir 
DF+emtricitabine+efavirenz (FTC/TDF+EFV), tenofovir DF+emtricitabine+ritonavir+ 
lopinavir (FTC/TDF+LPV/r), tenofovir DF+emtricitabine+ darunavir (FTC/TDF+ DRV+ 
r), and elvitegravir+cobicistat+emtricitabine+tenofovir DF (STRIBILD). Methods: This 
analysis compares the HIV treatment alternatives of 3TC/AZT+ EFV, FTC/TDF+EFV, FTC/
TDF+LPV/r, FTC/TDF+DRV+ r and STRIBILD. The adherence rates were calculated from 
the increase rate in CD4 cell count and the risk of hospitalization as the effectiveness 
values. The data were taken from patient files from Hacettepe University that consists 
of 252 patients and 12 year follow-ups with an outpatient clinic, interventions, labora-
tory and imaging tests, medication usage, side effects, comorbidity’s diseases and their 
treatments and complications. The costs of treatment of diseases were calculated by 
cost of disease methodology. Average annual cost per patient is calculated for health 
care technologies. Health technology effectiveness values are found from the literature 
review. Virological response success is used from clinical studies as an end-point for 
this analysis. The treatment cost comparison is calculated with the incremental cost 
effectiveness-ratio (ICER). Results: Results of the clinical effectiveness of the treat-
ment alternatives of 3TC/AZT+ EFV, FTC/TDF + EFV, FTC/TDF +LPV/r, FTC/TDF+ DRV+ 
r and STRIBILD were 58%, 75%, 78%, 84%, and 88%, respectively. In the cost -effective-
ness comparison analysis, the annual total treatment costs are calculated as 12531 
TL, 17524 TL, 24284 TL, 22987 TL, and 20868 TL, respectively. The total ICER analysis 
shows only STRIBILD, FTC/TDF+EFV and 3TC/AZT+EFV treatments are cost-effective, 
while the other treatment alternatives are not cost-effective. ConClusions: The HIV-1 
treatment study was conducted in Turkey on the cost-effectiveness of this treatment 
strategy. The clinical efficacy and the cost-effectiveness of STRIBILD shows that it is an 
effective treatment strategy for HIV patients.
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objeCtives: To perform comparative pharmacoeconomic analysis of ertapenem in 
patients with community-acquired complicated intraabdominal infection in com-
parison with alternative therapy moxifloxacin. Methods: Were reviewed research 
on the clinical effectiveness and safety of use of ertapenem to prevent postoperative 
inflammatory complications and lethal outcomes. Assess of the quality of research 
and level of evidence obtained in these results was performed. The results of the 
research PROMISE formed the basis of pharmacoeconomic model. The effectiveness 
of therapy in studies was assessed by the frequency of clinical and bacteriological 
success of treatment with the use of different modes of antibacterial therapy. We 
calculated the difference in direct medical costs for treatment by ertapenem and 
moxifloxacin and cost-effectiveness ratio. Results: According to a study J. J. De 
Waele et al., in patients treated with ertapenem, the frequency of clinical effect of 
treatment was higher than in the group of patients receiving moxifloxacin: 93,4% 
and 89.5%, respectively. The mortality rate associated with the development of 
severe sepsis, was also lower for ertapenem: 3,1% and 5.4% respectively. Direct 
medical costs accounted in the group of moxifloxacin with the average duration 
of therapy is 7 days was 1798 USD, in the group of ertapenem with the average 
duration of treatment 6.8 days - 1981 USD. When using moxifloxacin instead of 
ertapenem ICER for one additional prevented complication was 4688 USD, and for 
one surviving patient - 17027 USD. One way sensitivity analyses showed that the 
results of the model were not sensitive to changing the cost of ertapenem from 75% 
to 125 %. ConClusions: Pharmacoeconomic analysis showed that the application 
of ertapenem for the treatment of community-acquired complicated intra-abdom-
inal infections is expensive but more efficient and economically justified strategy.
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objeCtives: The seasonal trivalent influenza vaccine (TIV) covers two subtypes 
of influenza A (A/H1N1 and A/H3N2) plus one of the two influenza B lineages cir-
culating in humans. Co-circulation of both influenza B lineages (B/Victoria and 
B/Yamagata) was common in Hong Kong. We examined the difference in costs 
and quality-adjusted life-years (QALYs) gained by quadrivalent influenza vaccine 
